European Market Report for Lancet and Lancing Devices 2016 - MedCore
|出版商||iData Research Inc.||商品編碼||370719|
|出版日期||內容資訊||英文 94 Pages
|歐洲的血糖檢測用採血針、穿刺設備市場 European Market Report for Lancet and Lancing Devices 2016 - MedCore|
|出版日期: 2016年09月01日||內容資訊: 英文 94 Pages||
The value of the lancet and lancing device increased in 2015 and modest growth is expected to continue over the forecast period, driven by increasing unit sales and limited by ASP erosion. Unit sales growth will be driven by the increasing patient population and as a result, increasing number of diabetics that are testing their blood glucose levels. However, unit sales growth will be moderated by the continuing trend of manufacturers giving away complimentary lancet and lancing devices to patients, as well as lancet reuse among the diabetic population. ASP erosion will also be driven by the existence of complimentary devices and by the growth of low-price competitors in the lancet and lacing device market. Typically, lancets are sold in packs of 100 or 200, but some are sold in packs of 25, 102, 204 and other combinations. For this reason, ASP is quoted on a per lancet basis.
A lancet is a small needle with a plastic or rubber coating that fits into the top of a lancing device. Lancing devices are pen-like instruments which are used in conjunction with a lancet to draw blood to be applied to a glucose strip. Many lancets come as a component of blood glucose monitoring kits, and can be adjusted for injection depth. Reusable lancets are not as effective as they are more dull and painful and increase the risk of infection.